What happened to Telix Pharmaceutical (TLX) shares today?
TLX -15.4%: the oncology company announced that they have pulled an application to market into Europe. The Danish Medicines Agency requested further testing numbers for their manufacturing practices to confirm the safety of Telix’s Illuccix product. The radioactive product is used in prostate cancer imaging and was on track for its first EU sales by mid-2023. The company expects to resubmit the application with the additional requests however they would not put a timeframe on the filing.
Wondering what Market Matters are buying and selling today?
Market Matters breaks down the latest financial developments into simple, actionable opinion that our members can rely on. We give our community access to some of the most trusted financial professionals in Australia and crucially, we invest in our own portfolios – putting real money where our mouth is.
Led by James Gerrish, the Market Matters Investment Team has decades of market experience, and every day we’ll give you our take on the market. With in-depth market analytics, clear buy, hold and sell actions members can quickly see the stocks we like, the stocks we don’t and the history behind every one of our decisions.
See for yourself – take an obligation free 14 day trial of our service – here.
